Difference between revisions of "Part:BBa K3924035"
Yiyuan-h19 (Talk | contribs) |
Yiyuan-h19 (Talk | contribs) |
||
Line 20: | Line 20: | ||
As our engineered probiotics are to be used in IBD treatment as prescribed drugs instead of dietary supplements, we deem it unnecessary to incorporate conditional promoters into our design. We therefore use the constitutive expression plasmid pMG36e as the backbone. Also, being a transfer plasmid, pMG36e can replicate in both E.coli and L.lactis, which saved us a lot of trouble in transformation.<br/> | As our engineered probiotics are to be used in IBD treatment as prescribed drugs instead of dietary supplements, we deem it unnecessary to incorporate conditional promoters into our design. We therefore use the constitutive expression plasmid pMG36e as the backbone. Also, being a transfer plasmid, pMG36e can replicate in both E.coli and L.lactis, which saved us a lot of trouble in transformation.<br/> | ||
In addition, to facilitate the verification of protein expression, a 6xHIS-tag was added to the N-terminal of BSH1 gene. | In addition, to facilitate the verification of protein expression, a 6xHIS-tag was added to the N-terminal of BSH1 gene. | ||
− | [[Image: T--Tsinghua--BSH1_plasmid.png|'''Figure 1: The design of BSH1''']] | + | [[Image: T--Tsinghua--BSH1_plasmid.png|center|600px|thumb|'''Figure 1: The design of BSH1''']] |
==Functional Verification== | ==Functional Verification== | ||
===Validation based on protein expression level=== | ===Validation based on protein expression level=== | ||
After sequencing of synthetic plasmid (by company), We transformed the plasmid into E.coli chemocompetent cells (Stellar, Takara) to amplify it. Then we transferred the plasmid to Lactococcus lactis. After overnight shaking culture, cells were harvested and lysed for Westen Blot. The result is shown below: | After sequencing of synthetic plasmid (by company), We transformed the plasmid into E.coli chemocompetent cells (Stellar, Takara) to amplify it. Then we transferred the plasmid to Lactococcus lactis. After overnight shaking culture, cells were harvested and lysed for Westen Blot. The result is shown below: | ||
− | [[Image: BSH1_WesternBlot.png|'''Figure 2: The Western Blot Result''']] | + | [[Image: BSH1_WesternBlot.png|center|600px|thumb|'''Figure 2: The Western Blot Result''']] |
==Reference== | ==Reference== |
Revision as of 16:05, 20 October 2021
BSH1
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Profile
Name: BSH1
Base Pairs: 993bp
Origin: Lactobacillus salivarius, synthetic
Properties: A bile salt hydrolase catalyzing the hydrolysis of primary bile acids
Usage and Biology
BSH1 is a bile salt hydrolase from Lactobacillus salivarius. It catalyzes deconjugation of glyco-conjugated and tauro-conjugated bile acids through the hydrolysis of the amide bond and the release of free bile acids (e.g. cholic acid, deoxycholic acid or chenodeoxycholic acid) and amino acids (glycine or taurine)[1]. Deconjugation is a rate-limiting reaction in the metabolism of bile acids in the small intestine[2][3]. Therefore, BSH participates in a range of metabolic processes in mammalians including the regulation of dietary lipid absorption, cholesterol metabolism, energy and inflammation homeostasis.[4][5][6]According to existing literature, BSH1 has been successfully expressed in L.lactis and was shown to function well.[7]Based on these, we plan to express BSH1 in the well-characterized probiotic strain Lactococcus lactis to hydrolyse primary bile acids in the intestine, promoting the production of the more benefitial secondary bile acids. [8]
Design and Construction
As our engineered probiotics are to be used in IBD treatment as prescribed drugs instead of dietary supplements, we deem it unnecessary to incorporate conditional promoters into our design. We therefore use the constitutive expression plasmid pMG36e as the backbone. Also, being a transfer plasmid, pMG36e can replicate in both E.coli and L.lactis, which saved us a lot of trouble in transformation.
In addition, to facilitate the verification of protein expression, a 6xHIS-tag was added to the N-terminal of BSH1 gene.
Functional Verification
Validation based on protein expression level
After sequencing of synthetic plasmid (by company), We transformed the plasmid into E.coli chemocompetent cells (Stellar, Takara) to amplify it. Then we transferred the plasmid to Lactococcus lactis. After overnight shaking culture, cells were harvested and lysed for Westen Blot. The result is shown below:
Reference
[1] Grill, J., Schneider, F., Crociani, J., & Ballongue, J. (1995). Purification and characterization of conjugated bile salt hydrolase from Bifidobacterium longum BB536. Applied and environmental microbiology, 61(7), 2577-2582.
[2] Geng, W., & Lin, J. (2016). Bacterial bile salt hydrolase: an intestinal microbiome target for enhanced animal health. Animal health research reviews, 17(2), 148-158.
[3] Begley, M., Hill, C., & Gahan, C. G. (2006). Bile salt hydrolase activity in probiotics. Applied and environmental microbiology, 72(3), 1729-1738.
[4] Joyce, S. A., Shanahan, F., Hill, C., & Gahan, C. G. (2014). Bacterial bile salt hydrolase in host metabolism: potential for influencing gastrointestinal microbe-host crosstalk. Gut microbes, 5(5), 669-674.
[5] Nguyen, A., & Bouscarel, B. (2008). Bile acids and signal transduction: role in glucose homeostasis. Cellular signalling, 20(12), 2180-2197.
[6] Yadav, R., & Shukla, P. (2017). An overview of advanced technologies for selection of probiotics and their expediency: a review. Critical reviews in food science and nutrition, 57(15), 3233-3242.
[7] Lavelle, A., & Sokol, H. (2020). Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nature reviews Gastroenterology & hepatology, 17(4), 223-237.
[8] Bi, J., Liu, S., Du, G., & Chen, J. (2016). Bile salt tolerance of Lactococcus lactis is enhanced by expression of bile salt hydrolase thereby producing less bile acid in the cells. Biotechnology letters, 38(4), 659-665.